Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced ...
Eli Lilly Buys Morphic for $3.2B
Eli Lilly agreed to buy biopharmaceutical firm Morphic for roughly $3.2 billion, sending shares of Morphic skyrocketing ...
WISH-TV on MSN2h
Lilly to acquire biopharmaceutical company Morphic; aims to improve results for IBD patients
Eli Lilly and Company announced Monday morning that it has reached an agreement to acquire biopharmaceutical company Morphic.
Ibj.com2h
Lilly to buy Massachusetts biopharma company for $3.2B
Massachusetts-based Morphic Holding Inc. is a nine-year old, publicly traded company that is developing a class of drugs known as oral integrin therapies to treat autoimmune diseases, pulmonary ...
Morphic Shares Soar In Pre-market On Acquisition By Eli Lilly
Shares of biopharmaceutical company Morphic Holding, Inc. (MORF) were surging more than 75 percent in pre-market on Monday on the ...
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...
Novo Nordisk, Eli Lilly singled out by Biden, Sanders over drug prices
Shares of Novo Nordisk and Eli Lilly & Co. dropped early Tuesday after President Joe Biden and Sen. Bernie Sanders criticized ...